Claims for Patent: 11,026,944

Summary for Patent: 11,026,944

Title:	Compositions and methods for treating insomnia
Abstract:	In the present invention, compound such as (1R,2S)-2-(((2,4-dimethylpyrimidin-5-yl)oxy)methyl)-2-(3-fluorophenyl)-N-(5-fluoropyridin-2-yl) cyclopropanecarboxamide have been found to be potent orexin receptor antagonists, and may be useful in the treatment of sleep disorders such as insomnia, as well as for other therapeutic uses.
Inventor(s):	Moline Margaret, Pastino Gina, Akimoto Yurie, Zaima Yasuhiro, Suzuki Nobuya, Yoshida Nobuo
Assignee:	Eisai R&D Management Co., Ltd.
Application Number:	US16819341
Patent Claims:	2. The dosage form of claim 1 , wherein said dosage form provides a dissolution rate of 85% or more in a dissolution medium (0.1 mol/L hydrochloric acid claim 1 , 900 mL claim 1 , 37±0.5° C.) within 15 minutes from the onset of a dissolution study using Apparatus 2 (Paddle Apparatus claim 1 , paddle speed; 50 rpm) according to the procedure for immediate-release dosage form in 6.10 Dissolution test of JP16 or <711>Dissolution of USP37.3. The dosage form of claim 1 , wherein said dosage form comprises lactose as a pharmaceutically acceptable excipient.4. The dosage form of claim 1 , wherein said dosage form comprises low-substituted hydroxypropyl cellulose as a pharmaceutically acceptable excipient.5. The dosage form of claim 1 , wherein said dosage form comprises lactose and low-substituted hydroxypropyl cellulose as pharmaceutically acceptable excipients.